信达生物(01801)与UNION达成战略合作 引进用于治疗炎症性皮肤病的下一代PDE4抑制剂

2021-09-28 信达生物 信达生物

信达生物(01801)发布公告,该公司与UNION Therapeutics A/S (UNION),宣布双方就UNION用于治疗炎症性皮肤病的主要候选药物 orismilast —&md

信达生物(01801)发布公告,该公司与UNION Therapeutics A/S (UNION),宣布双方就UNION用于治疗炎症性皮肤病的主要候选药物 orismilast ——一款处于临床2期的潜在同类最佳PDE4抑制剂,达成在中国(包括中国大陆、中国香港、中国澳门和中国台湾)的独家授权协议。

根据协定条款,信达生物将获得orismilast在中国研究、开发和商业化的独家权益。UNION将收到2000万美元的首付款,并有权获得累计不超过2.47亿美元的里程碑付款,以及orismilast在中国年度销售净额的特许权使用费。UNION保留 orismilast在除中国以外的全球其他地区的权益。

中国大约有5000万特应性皮炎患者和600万银屑病患者,且发病率随着生活方式的改变显示出逐步上升的趋势。目前标准治疗方法为外用类固醇、口服免疫抑制剂和注射类生物制剂,在疗效、安全性或给药途径上有一定的局限性,存在明显的未满足临床需求。在2a期临床研究中,orismilast表现出潜在的同类最佳 (best-in-class)潜质,显示出更好的抗炎作用,以及通过创新的缓释方式获得更好的耐受性,有望解决炎症性皮肤病患者群体的未满足需求。

同时,银屑病、特应性皮炎、化脓性皮炎等炎症性皮肤病属于常见的慢性自免风湿疾病,与本公司疾病领域的战略布局和研究资源高度契合。此次合作为本公司的现有研发管线增加了一个处于临床开发中期的潜在最佳候选药物。本公司将全面负责orismilast中国区域临床开发和商业化工作。基于巨大的未满足需求和扎实的临床资料,本公司希望尽快将这一下一代同类最佳PDE4抑制剂尽快惠及中国的患者。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1852762, encodeId=65571852e62d3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 12 06:22:34 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826149, encodeId=cb1e1826149e4, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Aug 21 09:22:34 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465481, encodeId=4e3514654819a, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478281, encodeId=27b014e8281ee, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547477, encodeId=7658154e47770, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055760, encodeId=93fa1055e603d, content=太好了,皮肤病患者的**, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210612/4cac76eb29134c3aa63a2560971ec878/648fa1cb22cd430380c051eb0a8f6259.jpg, createdBy=7a8d5519826, createdName=呼吸科小医生, createdTime=Tue Sep 28 17:15:39 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055621, encodeId=044d1055621d2, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/3b8934f4fda746fb83ba232ba908d212/903d509a4836436c8e5358100808c1ac.jpg, createdBy=f9611930715, createdName=ljs忍冬花, createdTime=Tue Sep 28 11:12:48 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
    2022-05-12 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=1852762, encodeId=65571852e62d3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 12 06:22:34 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826149, encodeId=cb1e1826149e4, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Aug 21 09:22:34 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465481, encodeId=4e3514654819a, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478281, encodeId=27b014e8281ee, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547477, encodeId=7658154e47770, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055760, encodeId=93fa1055e603d, content=太好了,皮肤病患者的**, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210612/4cac76eb29134c3aa63a2560971ec878/648fa1cb22cd430380c051eb0a8f6259.jpg, createdBy=7a8d5519826, createdName=呼吸科小医生, createdTime=Tue Sep 28 17:15:39 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055621, encodeId=044d1055621d2, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/3b8934f4fda746fb83ba232ba908d212/903d509a4836436c8e5358100808c1ac.jpg, createdBy=f9611930715, createdName=ljs忍冬花, createdTime=Tue Sep 28 11:12:48 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1852762, encodeId=65571852e62d3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 12 06:22:34 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826149, encodeId=cb1e1826149e4, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Aug 21 09:22:34 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465481, encodeId=4e3514654819a, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478281, encodeId=27b014e8281ee, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547477, encodeId=7658154e47770, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055760, encodeId=93fa1055e603d, content=太好了,皮肤病患者的**, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210612/4cac76eb29134c3aa63a2560971ec878/648fa1cb22cd430380c051eb0a8f6259.jpg, createdBy=7a8d5519826, createdName=呼吸科小医生, createdTime=Tue Sep 28 17:15:39 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055621, encodeId=044d1055621d2, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/3b8934f4fda746fb83ba232ba908d212/903d509a4836436c8e5358100808c1ac.jpg, createdBy=f9611930715, createdName=ljs忍冬花, createdTime=Tue Sep 28 11:12:48 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1852762, encodeId=65571852e62d3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 12 06:22:34 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826149, encodeId=cb1e1826149e4, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Aug 21 09:22:34 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465481, encodeId=4e3514654819a, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478281, encodeId=27b014e8281ee, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547477, encodeId=7658154e47770, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055760, encodeId=93fa1055e603d, content=太好了,皮肤病患者的**, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210612/4cac76eb29134c3aa63a2560971ec878/648fa1cb22cd430380c051eb0a8f6259.jpg, createdBy=7a8d5519826, createdName=呼吸科小医生, createdTime=Tue Sep 28 17:15:39 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055621, encodeId=044d1055621d2, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/3b8934f4fda746fb83ba232ba908d212/903d509a4836436c8e5358100808c1ac.jpg, createdBy=f9611930715, createdName=ljs忍冬花, createdTime=Tue Sep 28 11:12:48 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1852762, encodeId=65571852e62d3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 12 06:22:34 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826149, encodeId=cb1e1826149e4, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Aug 21 09:22:34 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465481, encodeId=4e3514654819a, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478281, encodeId=27b014e8281ee, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547477, encodeId=7658154e47770, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055760, encodeId=93fa1055e603d, content=太好了,皮肤病患者的**, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210612/4cac76eb29134c3aa63a2560971ec878/648fa1cb22cd430380c051eb0a8f6259.jpg, createdBy=7a8d5519826, createdName=呼吸科小医生, createdTime=Tue Sep 28 17:15:39 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055621, encodeId=044d1055621d2, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/3b8934f4fda746fb83ba232ba908d212/903d509a4836436c8e5358100808c1ac.jpg, createdBy=f9611930715, createdName=ljs忍冬花, createdTime=Tue Sep 28 11:12:48 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1852762, encodeId=65571852e62d3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 12 06:22:34 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826149, encodeId=cb1e1826149e4, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Aug 21 09:22:34 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465481, encodeId=4e3514654819a, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478281, encodeId=27b014e8281ee, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547477, encodeId=7658154e47770, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055760, encodeId=93fa1055e603d, content=太好了,皮肤病患者的**, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210612/4cac76eb29134c3aa63a2560971ec878/648fa1cb22cd430380c051eb0a8f6259.jpg, createdBy=7a8d5519826, createdName=呼吸科小医生, createdTime=Tue Sep 28 17:15:39 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055621, encodeId=044d1055621d2, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/3b8934f4fda746fb83ba232ba908d212/903d509a4836436c8e5358100808c1ac.jpg, createdBy=f9611930715, createdName=ljs忍冬花, createdTime=Tue Sep 28 11:12:48 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
    2021-09-28 呼吸科小医生

    太好了,皮肤病患者的**

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1852762, encodeId=65571852e62d3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 12 06:22:34 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826149, encodeId=cb1e1826149e4, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Aug 21 09:22:34 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465481, encodeId=4e3514654819a, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478281, encodeId=27b014e8281ee, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547477, encodeId=7658154e47770, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Thu Sep 30 01:22:34 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055760, encodeId=93fa1055e603d, content=太好了,皮肤病患者的**, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210612/4cac76eb29134c3aa63a2560971ec878/648fa1cb22cd430380c051eb0a8f6259.jpg, createdBy=7a8d5519826, createdName=呼吸科小医生, createdTime=Tue Sep 28 17:15:39 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055621, encodeId=044d1055621d2, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/3b8934f4fda746fb83ba232ba908d212/903d509a4836436c8e5358100808c1ac.jpg, createdBy=f9611930715, createdName=ljs忍冬花, createdTime=Tue Sep 28 11:12:48 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
    2021-09-28 ljs忍冬花

    期待

    0

相关资讯

JAAD:窄谱紫外线 B 不同增量剂量方案对银屑病III-V 型皮肤治疗效果的比较

银屑病的首选治疗方法之一是窄谱紫外线 B (NB-UVB) 光疗。尽管 NB-UVB 被广泛使用,但关于合适的起始剂量和剂量增量的不同指南之间并不统一。

JEADV:替曲吉珠单抗 ( tildrakizumab )对中度至重度银屑病患者第28周停药后复发时间的研究

替曲吉珠单抗(Tildrakizumab) 是一种特异性单克隆抗体,靶向白细胞介素 (IL)-23 的 p19 亚基,已被批准用于治疗斑块状银屑病,已显示出长期有效性及安全性。

BJD:瑞莎珠单抗vs司库奇尤单抗在中度至重度斑块状银屑病患者中的疗效和安全性

Risankizumab(瑞莎珠单抗)和Suckinumab(司库奇尤单抗)分别抑制白细胞介素(IL)-23和IL-17A,对中重度斑块型银屑病成人患者有效,但给药方案不同。

一文了解头皮银屑病和脂溢性皮炎的皮肤镜鉴别

银屑病和脂溢性皮炎是相对常见的炎症性皮肤病,具体表现为红斑脱屑。这两种疾病有共同的临床病理特征,但皮肤镜检查时有一些明显的区别。

JAAD:Ixekizumab 的长期疗效和安全性

Ixekizumab 是一种有效的中度至重度斑块状银屑病治疗方法,具有良好的安全性特征。ixekizumab 疗法适用于斑块状银屑病患者的长期治疗。

BJD:司库奇尤单抗治疗中重度掌跖银屑病的持续疗效观察

Suckinumab已经在几种牛皮癣症状上显示出持续的有效性和安全性,包括指甲、头皮、手掌、足底和银屑病关节炎。